Apontis Pharma AG Logo

Apontis Pharma AG

German pharma firm specializing in Single Pills for cardiovascular and chronic diseases.

APPH | F

Overview

Corporate Details

ISIN(s):
DE000A3CMGM5 (+1 more)
LEI:
894500ETO1J6MR8PDF91
Country:
Germany
Address:
Alfred-Nobel-Straße 10, 40789 Monheim am Rhein
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

Apontis Pharma AG is a leading pharmaceutical company in Germany specializing in the development, marketing, and distribution of "Single Pills." These are fixed-dose combination drugs that integrate two to three active ingredients into a single tablet, primarily for treating cardiovascular diseases and other chronic conditions. The company's core strategy is to simplify medication regimens to improve patient adherence and therapeutic outcomes. Apontis Pharma maintains a broad portfolio of proprietary products and collaborates on strategic partnerships, leveraging its established access to a network of approximately 23,500 physicians to promote its offerings and provide related consulting and training services.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-08-20 16:00
Board/Management Information
APONTIS PHARMA: Changes in the management board
English 9.1 KB
2025-08-19 00:00
Interim Report
Half-yearly financial statements 2025
English 712.8 KB
2025-06-13 10:30
M&A Activity
APONTIS PHARMA AG: Merger Squeeze-out Cash Compensation Determined at EUR 10.40
English 7.2 KB
2025-05-15 07:30
Earnings Release
APONTIS PHARMA publishes results for the first quarter of 2025 and confirms for…
English 25.5 KB
2025-03-31 14:00
Earnings Release
APONTIS PHARMA with significant sales and earnings increase in 2024 financial y…
English 26.3 KB
2025-03-31 00:00
Annual Report
Annual financial statements 2024
English 1.3 MB
2025-03-06 20:50
M&A Activity
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
English 7.6 KB
2025-03-05 20:50
M&A Activity
APONTIS PHARMA AG: Zentiva AG submits formal request to carry out a merger sque…
English 7.6 KB
2024-12-23 00:00
Annual / Quarterly Financial Statement
Jahresabschluss zum Geschäftsjahr vom 01.01.2023 bis zum 31.12.2023
German 27.9 KB
2024-12-12 14:42
Director's Dealing
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
English 7.7 KB
2024-12-11 16:00
Director's Dealing
APONTIS PHARMA AG: Thomas Milz, Sale: The sale was made via a joint custody acc…
English 7.7 KB
2024-12-10 10:35
Director's Dealing
APONTIS PHARMA AG: Thomas Zimmermann, sell
English 7.5 KB
2024-11-27 00:00
Board/Management Information
Konzernabschluss zum Geschäftsjahr vom 01.01.2022 bis zum 31.12.2022
German 398.4 KB
2024-11-22 11:30
M&A Activity
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
English 14.2 KB
2024-11-21 11:30
M&A Activity
APONTIS PHARMA AG: Condition of Minimum Acceptance in Zentivas Voluntary Public…
English 14.2 KB

Automate Your Workflow. Get a real-time feed of all Apontis Pharma AG filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

No Financial Data Available

Standardized financial statements for the selected period are not yet available.

Need More History? Access decades of standardized financials for Apontis Pharma AG via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2024-05-14 Milz, Thomas Board Buy None 8,960.00 EUR
2024-05-14 be executive GmbH Close relation Buy None 8,880.00 EUR
2024-05-13 Zimmermann, Thomas Other Buy None 10,128.00 EUR
2024-05-13 Zimmermann, Thomas Other Buy None 3,396.00 EUR
2024-05-13 Zimmermann, Thomas Other Buy None 1,692.00 EUR
2024-05-13 Zimmermann, Thomas Other Buy None 1,688.00 EUR
2023-05-05 Reineke, Silke Close relation Buy None 36,625.00 EUR
2023-05-05 Milz, Thomas Board Buy None 14,360.00 EUR

Peer Companies

Company Country Ticker View
2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden 2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom 4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany VSC
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom ABDX
ABIONYX Pharma Logo
Biotech developing lipid-based therapies for rare renal and ophthalmological diseases.
France ABNX
Abliva Logo
Develops clinical-stage medicines for rare primary mitochondrial diseases to restore cell function.
Sweden ABLI
AB Science Logo
Develops protein kinase inhibitors for oncology, neuro, and inflammatory diseases.
France AB
Access Bio, Inc. Logo
Develops and manufactures rapid diagnostic tests for infectious diseases for global health.
United States of America 950130
Active Biotech Logo
Develops immunology-based drugs for cancer and inflammatory diseases with high unmet medical need.
Sweden ACTI

Talk to a Data Expert

Have a question? We'll get back to you promptly.